Biolinerx Ltd (BLRX) 0.86 $BLRX
BioLineRx to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York
PR Newswire - Mon Aug 29, 6:00AM CDT
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 18th Annual Rodman & Renshaw Global Investment Conference at the Lotte New York Palace Hotel in New York City.
BLRX: 0.86 (-0.02)
BioLineRx and I-Bridge Capital Establish a New Drug Development Joint Venture in China
PR Newswire - Thu Aug 25, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has established a joint venture (JV) with I-Bridge Capital, a Chinese venture capital fund focused on developing innovative therapies in China. The joint venture, named iPharma, will develop innovative clinical and pre-clinical therapeutic candidates originating primarily in Israel to serve the Chinese and global healthcare markets.
BLRX: 0.86 (-0.02)
BioLineRx Reports Second Quarter 2016 Financial Results
PR Newswire - Thu Aug 11, 6:15AM CDT
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the second quarter ended June 30, 2016.
BLRX: 0.86 (-0.02)
BioLineRx Names Philip A. Serlin as Chief Executive Officer
PR Newswire - Thu Aug 11, 5:45AM CDT
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Philip A. Serlin has been named Chief Executive Officer of BioLineRx, effective October 10, 2016.
VBLT: 4.09 (+0.03), BLRX: 0.86 (-0.02)
BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer
PR Newswire - Mon Aug 08, 6:00AM CDT
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the signing of a collaboration agreement with The University of Texas MD Anderson Cancer Center for the investigation of BL-8040 in combination with KEYTRUDA® (pembrolizumab) in pancreatic cancer. The study will be conducted as an investigator-sponsored study, as part of a strategic clinical research collaboration between MSD (known as Merck in the US and Canada) and MD Anderson Cancer Center aimed at evaluating Merck's anti-PD-1 therapy, KEYTRUDA, in combination with various treatments and novel drugs.
MRK: 62.98 (+0.08), BLRX: 0.86 (-0.02)
BioLineRx to Report Second Quarter Results on August 11, 2016
PR Newswire - Thu Aug 04, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its unaudited financial results for the quarter ended June 30, 2016, on Thursday, August 11, 2016, before the U.S. markets open.
BLRX: 0.86 (-0.02)
BioLineRx Announces In-licensing of Liver Fibrosis Project Under Strategic Collaboration
PR Newswire - Mon Aug 01, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed an exclusive worldwide agreement with Hadasit, the Technology Transfer Company of Hadassah Medical Organization, for the in-licensing of a drug candidate for the treatment of liver fibrosis, and in particular, non-alcoholic steatohepatitis (NASH). This drug candidate, to be called BL-1210, is the first project to be in-licensed under the framework of the Company's strategic collaboration with Novartis Pharma AG for the screening and development of novel drug candidates.
BLRX: 0.86 (-0.02)
BioLineRx's BL-8040 to be Presented at Upcoming Scientific Conferences
PR Newswire - Thu May 19, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that BL-8040, its lead platform for the treatment of multiple cancer and hematological indications, will be presented at two upcoming scientific conferences.
BLRX: 0.86 (-0.02)
BioLineRx Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 17, 7:04AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the first quarter ended March 31, 2016.
BLRX: 0.86 (-0.02)
BioLineRx and MaRS Innovation Sign Framework Collaboration Agreement
PR Newswire - Mon May 16, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed a framework collaboration agreement with MaRS Innovation, the commercialization agent for fifteen of Toronto's top academic institutions. Under the terms of the agreement, BioLineRx intends to review innovative projects and assets of startup companies originating from MaRS Innovation's members, in order to identify in-licensing, co-development or other partnering opportunities.
BLRX: 0.86 (-0.02)
BioLineRx Announces Presentation of Detailed Mechanism of Action Data for Lead Oncology Platform at AACR 2016
PR Newswire - Tue Apr 19, 7:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that detailed results from a study on the underlying mechanism of action of BL-8040, its lead platform for the treatment of multiple cancer and hematological indications, were presented by Prof. Amnon Peled at the American Association of Cancer Research (AACR) 2016 meeting in New Orleans.
BLRX: 0.86 (-0.02)
BioLineRx's Novel Treatment for Non-Surgical Removal of Skin Lesions Receives CE Mark Approval
PR Newswire - Mon Apr 04, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that its partner, Omega Pharma, now part of Perrigo, has received CE Mark approval for BL-5010 as a novel OTC treatment for the non-surgical removal of skin lesions. The product's commercial launch by Omega Pharma is expected by mid-2016. Subject to the terms of the licensing agreement with Omega Pharma, BioLineRx plans to provide updates at a later stage regarding the commercial potential of the product and its contribution to the Company's ongoing business.
PRGO: 90.75 (-0.50), BLRX: 0.86 (-0.02)
BioLineRx Receives Confirmation of Medical Device Classification in Europe for Celiac Treatment
PR Newswire - Mon Jan 25, 6:00AM CST
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received confirmation from the European Notified Body regarding the classification of BL-7010, a novel polymer for the treatment of celiac disease, as a Class IIb medical device in the European Union.
BLRX: 0.86 (-0.02)
BioLineRx to Present at Biotech Showcase 2016 Conference in San Francisco
PR Newswire - Mon Jan 04, 6:00AM CST
BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the Biotech Showcase 2016 Conference being held in San Francisco, CA.
BLRX: 0.86 (-0.02)
BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Stem Cell Mobilization Treatment
BusinessWire - Mon Dec 14, 6:00AM CST
BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the filing of regulatory submissions required to commence a Phase 2 trial for BL-8040 as a novel approach for mobilization and collection of bone marrow stem cells from the peripheral blood circulation. The trial is expected to commence shortly after receipt of regulatory approval, anticipated in the first quarter of 2016.
BLRX: 0.86 (-0.02)
Bioline RX (BLRX) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Fri Dec 04, 8:37AM CST
As of late, it has definitely been a great time to be an investor in Bioline RX Ltd (BLRX)
BLRX: 0.86 (-0.02)
BioLineRx Establishes Oncology Scientific Advisory Board
BusinessWire - Thu Dec 03, 6:00AM CST
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported the establishment of a Scientific Advisory Board (SAB) to provide insight and guidance on the Company's activities in the field of oncology.
BLRX: 0.86 (-0.02)
BioLineRx (BLRX) Worth Watching: Stock Rises 11.3%
Zacks Equity Research - Zacks Investment Research - Wed Dec 02, 7:00AM CST
BioLineRx (BLRX) was a big mover last session, with its shares rising over 11% on the day.
CORT: 5.31 (-0.04), BLRX: 0.86 (-0.02)
BioLineRx Ltd. to Host Investor Breakfast in New York on December 3, 2015
BusinessWire - Wed Nov 25, 6:00AM CST
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it will host an investor breakfast on Thursday, December 3, 2015, in New York City.
BLRX: 0.86 (-0.02)
BioLineRx to Present at the LD Micro Main Event
BusinessWire - Tue Nov 24, 6:00AM CST
BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the LD Micro Main Event on December 2, 2015. The presentation will take place at 10:00 a.m. PST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.
BLRX: 0.86 (-0.02)
BioLineRx to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York
PR Newswire - Mon Aug 29, 6:00AM CDT
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 18th Annual Rodman & Renshaw Global Investment Conference at the Lotte New York Palace Hotel in New York City.
BLRX: 0.86 (-0.02)
BioLineRx and I-Bridge Capital Establish a New Drug Development Joint Venture in China
PR Newswire - Thu Aug 25, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has established a joint venture (JV) with I-Bridge Capital, a Chinese venture capital fund focused on developing innovative therapies in China. The joint venture, named iPharma, will develop innovative clinical and pre-clinical therapeutic candidates originating primarily in Israel to serve the Chinese and global healthcare markets.
BLRX: 0.86 (-0.02)
BioLineRx Reports Second Quarter 2016 Financial Results
PR Newswire - Thu Aug 11, 6:15AM CDT
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the second quarter ended June 30, 2016.
BLRX: 0.86 (-0.02)
BioLineRx Names Philip A. Serlin as Chief Executive Officer
PR Newswire - Thu Aug 11, 5:45AM CDT
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Philip A. Serlin has been named Chief Executive Officer of BioLineRx, effective October 10, 2016.
VBLT: 4.09 (+0.03), BLRX: 0.86 (-0.02)
BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer
PR Newswire - Mon Aug 08, 6:00AM CDT
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the signing of a collaboration agreement with The University of Texas MD Anderson Cancer Center for the investigation of BL-8040 in combination with KEYTRUDA® (pembrolizumab) in pancreatic cancer. The study will be conducted as an investigator-sponsored study, as part of a strategic clinical research collaboration between MSD (known as Merck in the US and Canada) and MD Anderson Cancer Center aimed at evaluating Merck's anti-PD-1 therapy, KEYTRUDA, in combination with various treatments and novel drugs.
MRK: 62.98 (+0.08), BLRX: 0.86 (-0.02)
BioLineRx to Report Second Quarter Results on August 11, 2016
PR Newswire - Thu Aug 04, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its unaudited financial results for the quarter ended June 30, 2016, on Thursday, August 11, 2016, before the U.S. markets open.
BLRX: 0.86 (-0.02)
BioLineRx Announces In-licensing of Liver Fibrosis Project Under Strategic Collaboration
PR Newswire - Mon Aug 01, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed an exclusive worldwide agreement with Hadasit, the Technology Transfer Company of Hadassah Medical Organization, for the in-licensing of a drug candidate for the treatment of liver fibrosis, and in particular, non-alcoholic steatohepatitis (NASH). This drug candidate, to be called BL-1210, is the first project to be in-licensed under the framework of the Company's strategic collaboration with Novartis Pharma AG for the screening and development of novel drug candidates.
BLRX: 0.86 (-0.02)
BioLineRx's BL-8040 to be Presented at Upcoming Scientific Conferences
PR Newswire - Thu May 19, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that BL-8040, its lead platform for the treatment of multiple cancer and hematological indications, will be presented at two upcoming scientific conferences.
BLRX: 0.86 (-0.02)
BioLineRx Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 17, 7:04AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the first quarter ended March 31, 2016.
BLRX: 0.86 (-0.02)
BioLineRx and MaRS Innovation Sign Framework Collaboration Agreement
PR Newswire - Mon May 16, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed a framework collaboration agreement with MaRS Innovation, the commercialization agent for fifteen of Toronto's top academic institutions. Under the terms of the agreement, BioLineRx intends to review innovative projects and assets of startup companies originating from MaRS Innovation's members, in order to identify in-licensing, co-development or other partnering opportunities.
BLRX: 0.86 (-0.02)
BioLineRx Announces Presentation of Detailed Mechanism of Action Data for Lead Oncology Platform at AACR 2016
PR Newswire - Tue Apr 19, 7:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that detailed results from a study on the underlying mechanism of action of BL-8040, its lead platform for the treatment of multiple cancer and hematological indications, were presented by Prof. Amnon Peled at the American Association of Cancer Research (AACR) 2016 meeting in New Orleans.
BLRX: 0.86 (-0.02)
BioLineRx's Novel Treatment for Non-Surgical Removal of Skin Lesions Receives CE Mark Approval
PR Newswire - Mon Apr 04, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that its partner, Omega Pharma, now part of Perrigo, has received CE Mark approval for BL-5010 as a novel OTC treatment for the non-surgical removal of skin lesions. The product's commercial launch by Omega Pharma is expected by mid-2016. Subject to the terms of the licensing agreement with Omega Pharma, BioLineRx plans to provide updates at a later stage regarding the commercial potential of the product and its contribution to the Company's ongoing business.
PRGO: 90.75 (-0.50), BLRX: 0.86 (-0.02)
BioLineRx Receives Confirmation of Medical Device Classification in Europe for Celiac Treatment
PR Newswire - Mon Jan 25, 6:00AM CST
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received confirmation from the European Notified Body regarding the classification of BL-7010, a novel polymer for the treatment of celiac disease, as a Class IIb medical device in the European Union.
BLRX: 0.86 (-0.02)
BioLineRx to Present at Biotech Showcase 2016 Conference in San Francisco
PR Newswire - Mon Jan 04, 6:00AM CST
BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the Biotech Showcase 2016 Conference being held in San Francisco, CA.
BLRX: 0.86 (-0.02)
BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Stem Cell Mobilization Treatment
BusinessWire - Mon Dec 14, 6:00AM CST
BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the filing of regulatory submissions required to commence a Phase 2 trial for BL-8040 as a novel approach for mobilization and collection of bone marrow stem cells from the peripheral blood circulation. The trial is expected to commence shortly after receipt of regulatory approval, anticipated in the first quarter of 2016.
BLRX: 0.86 (-0.02)
Bioline RX (BLRX) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Fri Dec 04, 8:37AM CST
As of late, it has definitely been a great time to be an investor in Bioline RX Ltd (BLRX)
BLRX: 0.86 (-0.02)
BioLineRx Establishes Oncology Scientific Advisory Board
BusinessWire - Thu Dec 03, 6:00AM CST
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported the establishment of a Scientific Advisory Board (SAB) to provide insight and guidance on the Company's activities in the field of oncology.
BLRX: 0.86 (-0.02)
BioLineRx (BLRX) Worth Watching: Stock Rises 11.3%
Zacks Equity Research - Zacks Investment Research - Wed Dec 02, 7:00AM CST
BioLineRx (BLRX) was a big mover last session, with its shares rising over 11% on the day.
CORT: 5.31 (-0.04), BLRX: 0.86 (-0.02)
BioLineRx Ltd. to Host Investor Breakfast in New York on December 3, 2015
BusinessWire - Wed Nov 25, 6:00AM CST
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it will host an investor breakfast on Thursday, December 3, 2015, in New York City.
BLRX: 0.86 (-0.02)
BioLineRx to Present at the LD Micro Main Event
BusinessWire - Tue Nov 24, 6:00AM CST
BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the LD Micro Main Event on December 2, 2015. The presentation will take place at 10:00 a.m. PST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.
BLRX: 0.86 (-0.02)
